Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein that acts as an intracellular calcium signal transducer, frequently overexpressed in cancer and associated with poor ...

In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...

A novel computational framework revolutionizes antibody design, offering precise predictions and unlocking insights into the immune system ... sequencing of B-cell receptors has generated ...

Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers.

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a headline value of $780 million to apply its multi-payload linker technology ...

IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors ...